Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2024 |
Sponsor / Collaborator |
Start Date06 May 2024 |
Sponsor / Collaborator |
Start Date01 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
17j | Tuberculosis More | Preclinical |
C-10 | Tuberculosis More | Preclinical |
APD-514 | Adenoviridae Infections More | Discontinued |
UCM-03025 ( MAGL ) | Multiple Sclerosis More | Pending |